Supplier log in
Future Procurement Opportunity (FPO) – Supply of permanent coronary drug eluting stents under a market share arrangement
Details
|
Tender Closed
|
|
| RFx ID : | 31681233 |
| Tender Name : | Future Procurement Opportunity (FPO) – Supply of permanent coronary drug eluting stents under a market share arrangement |
| Reference # : | qA73751 |
| Open Date : | Q2 2025 |
| Indicative RFx Release Date : | Q3 2025 [?] |
| Tender Type : | Future Procurement Opportunity (FPO) |
| Project Status : | Initial development [?] |
| Indicative Total Value : | $10M - $25M [?] |
| Expected number of contracts offered : | 1 |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Required Pre-qualifications : | None |
| Contact : |
Pharmac Procurement Team procurement@Pharmac.govt.nz |
| Related Tenders: | |
Pharmac plans to issue a single-stage Request for Proposals (RFP) for the supply of permanent coronary drug-eluting stents under a market share arrangement. Currently, Pharmac has a market share arrangement with a single supplier for permanent coronary drug-eluting stents, with a minimum market share of 65% guaranteed under its agreement.
The approximate gross annual expenditure of all permanent coronary drug eluting stents in the 2023/2024 financial year was $6,124,000. Under the current market share Health New Zealand | Te Whatu Ora hospitals are expected to use the successful supplier for a minimum of 65% of their usage.
As part of the upcoming RFP process, Pharmac will seek expert advice from a range of a health care professionals, technical experts and consumers about the use of permanent coronary drug-eluting stents to inform this work.
Further detail and notification of approval for the current market share arrangement is available on Pharmac’s website.
• Permanent coronary drug eluting stents (https://www.pharmac.govt.nz/hospital-devices/whats-happening-in-each-category/permanent-coronary-drug-eluting-stents)
